Clinical trial
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers…
NCT00291057 · Sun Pharmaceutical Industries, Inc., Industry · Terminated
Key facts
| NCT number | NCT00291057 |
|---|---|
| Title | Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice |
| Official title | Phase II, Multi-center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis |
| Lead sponsor | Sun Pharmaceutical Industries, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lice Infestations |
| Intervention type | Drug |
| Interventions | MALG |
| Enrollment | 30 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Feb 13, 2006 |
| Last update posted | Dec 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: